Resomer Rg 750 S Bioresorbable Plga Drug Delivery Grade

RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade

    • Product Name: RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade
    • Factroy Site: Yinchuan, Ningxia, China
    • Price Inquiry: sales8@ascent-chem.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    VTB
    Specifications
    HS Code 344504
    Productname RESOMER RG 750 S
    Manufacturer Evonik Industries
    Tradename RESOMER
    Chemicalname Poly(D,L-lactide-co-glycolide)
    Abbreviation PLGA
    Monomerratio 75:25 (D,L-lactide:glycolide)
    Endgroup Ester-capped
    Inherentviscosity 0.7 dL/g (typical, chloroform, 25°C)
    Appearance White to off-white granules or powder
    Form Granules or powder
    Solubility Soluble in chloroform, dichloromethane, ethyl acetate, and acetone; insoluble in water
    Glasstransitiontemperature 50-55°C
    Degradationtime 4-6 months
    Storageconditions Store at -20°C, protected from moisture, light, and heat
    Casnumber 26780-50-7
    Application Sustained-release drug delivery, microspheres, and implants
    Grade Drug Delivery Grade
    Sterilizationmethod Gamma irradiation or ethylene oxide
    Packaging 1 g, 5 g, 10 g, and 50 g
    Moisturecontent <0.5%
    Residualmonomer <0.5%
    Heavymetals <10 ppm

    As an accredited RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade supplied in 1 g, 5 g, and 100 g sealed, desiccated amber glass bottles.
    Container Loading (20′ FCL) 20′ FCL container loaded with RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade, palletized, securely stowed, and sealed for pharmaceutical transport.
    Shipping RESOMER RG 750 S is shipped as a non-hazardous, moisture-sensitive solid in sealed, moisture-barrier containers. Keep dry and protect from heat, moisture, and contamination. Store refrigerated or frozen per manufacturer instructions; use insulated, temperature-controlled packaging if required. Follow all supplier handling and transport guidelines.
    Storage Store RESOMER RG 750 S in its original, tightly sealed container at 2–8 °C (refrigerated), protected from moisture and light. Keep in a dry, well-ventilated area away from heat and ignition sources. Allow to equilibrate to room temperature before opening to avoid condensation. For extended storage, use an inert atmosphere and desiccant.
    Shelf Life Shelf life is typically 24 months when stored unopened at –20°C, protected from moisture; avoid heat, light, and repeated temperature cycling.
    Application of RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade

    In a long-acting injectable microsphere process based on RESOMER RG 750 S, a poly(D,L-lactide-co-glycolide) with a nominal lactide-to-glycolide ratio of 75:25, the organic phase is prepared by dissolving the polymer in dichloromethane at 10–25% w/w, while the active pharmaceutical ingredient is added at a drug-to-polymer ratio of 1:5 to 1:20 for peptide products and 1:5 to 1:10 for many small molecules requiring high encapsulation efficiency. The organic phase is emulsified into an aqueous continuous phase containing 1–2% w/w polyvinyl alcohol using a rotor-stator homogenizer at 6,000–10,000 rpm or an inline static mixer, producing an oil-in-water emulsion with a dispersed phase ratio of 1:10 to 1:50. Solvent removal is performed under a ramped temperature profile of 25–35°C and controlled vacuum, with residual dichloromethane reduced below the ICH Q3C Option 1 limit of 600 ppm before terminal lyophilization. Compliance for this parenteral process is defined by USP <71> sterility testing, USP <85> bacterial endotoxin testing, USP <788> particulate matter for injections, USP <790> visible particulates, USP <467> residual solvent analysis, and the Ph. Eur. poly(lactic-co-glycolide) monograph for polymer identity, residual monomer, and molecular mass distribution. The lyophilized cake is released with a Karl Fischer moisture specification below 1.0% w/w and a particle size distribution controlled to a Dv50 of 20–100 µm with D90 below 150 µm for intramuscular or subcutaneous depot injection. The terminal dosage form is a sterile, single-dose or multi-dose Type I borosilicate glass vial containing a lyophilized microsphere powder with butyl rubber closure, reconstituted with an aqueous vehicle before administration.

    What Controls Burst Release in an In-Situ Forming Depot Prepared with NMP?

    The burst release behavior of an in-situ forming depot prepared from RESOMER RG 750 S is governed primarily by solvent–water exchange, polymer concentration, and the viscosity of the organic solution at the moment of subcutaneous injection. The grade is dissolved in N-methyl-2-pyrrolidone or dimethyl sulfoxide at 20–45% w/w, while the API is loaded at 1–10% w/w; dissolution is performed at 25–40°C under nitrogen, and the resulting solution is sterile-filtered through a 0.2 µm PVDF membrane only when the viscosity remains below approximately 500 mPa·s. Above this viscosity, sterile filtration flux collapses and aseptic processing with pre-sterilized polymer and solvent is required; heat sterilization of the polymer solution is avoided because temperatures above 40°C accelerate ester hydrolysis in the presence of residual water. After injection, the water-miscible solvent diffuses into tissue fluid and the polymer precipitates as a bioerodible depot; formulations below 35% w/w PLGA typically show a higher 24-hour burst because the lower viscosity allows faster solvent efflux, while formulations at 40–45% w/w form a denser skin and slow the solvent exchange. Residual NMP is controlled below 530 ppm under ICH Q3C Option 1, and DMSO below 5,000 ppm under Class 3 guidance when used. Compliance includes 21 CFR Part 211, USP <71>, USP <85>, USP <790>, and ISO 10993-1:2018 clause 5.3 for biological evaluation. The terminal product is a single-use prefilled syringe or septum-sealed vial containing a sterile organic depot solution that forms an implant in situ after subcutaneous or intramuscular administration.

    ICH Q3C residual solvent thresholds relevant to RESOMER RG 750 S downstream processing
    SolventICH Q3C classificationPermitted daily exposureOption 1 concentration limit
    DichloromethaneClass 26.0 mg/day600 ppm
    N-methyl-2-pyrrolidoneClass 25.3 mg/day530 ppm
    ChloroformClass 20.6 mg/day60 ppm
    AcetoneClass 350 mg/day5,000 ppm
    Dimethyl sulfoxideClass 350 mg/day5,000 ppm

    Using RESOMER RG 750 S in nanoprecipitation, the organic phase consists of acetone or acetone-ethanol at a polymer concentration of 5–20 mg/mL, while the API is incorporated at a drug-to-polymer ratio of 1:5 to 1:20; polyvinyl alcohol at 0.5–2.0% w/w or poloxamer 188 at 0.1–1.0% w/w serves as the aqueous-phase stabilizer. The organic phase is injected into the aqueous phase through a confined impingement jet mixer or T-junction at a flow-rate ratio of 1:10 to 1:20, producing nanoparticles with a Z-average of 100–300 nm and a polydispersity index below 0.2. Residual acetone is removed by tangential flow filtration or rotary evaporation to below 5,000 ppm under ICH Q3C Class 3 guidance; for parenteral nanosuspensions, USP <788> particulate matter limits, USP <790> visible particulate limits, USP <85> endotoxin limits, and ISO 10993-1:2018 biocompatibility requirements apply. Basic APIs with tertiary amine groups can accelerate hydrolytic chain scission within the PLGA matrix, so forced degradation at 40°C/75% RH and drug-polymer compatibility screening are required before pivotal batch manufacture. The terminal product is either a lyophilized nanoparticle cake in a sterile vial, reconstituted before intravenous or mucosal administration, or a concentrated sterile nanosuspension in a single-use injection system.

    Residence Time and Melt Pressure in Subcutaneous Implant Extrusion

    Prior to hot-melt extrusion of RESOMER RG 750 S, the polymer is pre-dried under vacuum at 25–30°C for 24–48 h to a residual moisture below 0.5% w/w, particularly when ambient relative humidity exceeds 60%. The predried polymer is blended with the API at 5–30% w/w, a plasticizer such as polyethylene glycol 1500 or triethyl citrate at 0–10% w/w, and RESOMER RG 750 S to 100% w/w. The blend is processed through a twin-screw extruder with an L/D ratio of 25:1 to 40:1, barrel temperatures of 80–120°C, screw speed of 20–100 rpm, and die pressure monitored between 10 bar and 50 bar; residence time is kept below 3 min to limit thermal hydrolysis, which would reduce molecular weight and shift the release profile. The extrudate is cut into sterile subcutaneous implant rods with a diameter of 1.5–2.0 mm and a length of 1–3 cm, then sealed in a double-foil pouch or pre-loaded inserter. Compliance includes ISO 10993-1:2018, USP <71>, USP <85>, USP <790>, and 21 CFR Part 211; polymer-related release criteria follow the Ph. Eur. poly(lactic-co-glycolide) monograph for residual monomers, heavy metals, and molecular mass distribution. The terminal dosage form is a sterile, prefilled subcutaneous rod implant for sustained hormone or peptide delivery.

    When RESOMER RG 750 S Is Applied as a Biodegradable Drug-Eluting Stent Coating

    When RESOMER RG 750 S is applied as a drug-eluting stent coating, the coating solution is prepared in a chloroform-acetone mixture at 70:30 v/v with a polymer concentration of 0.5–2.5% w/v, and the antiproliferative agent is added at a drug-to-polymer ratio of 1:1 to 1:3. The solution is delivered by coaxial ultrasonic spray coating onto cobalt-chromium or stainless steel stent platforms at a flow rate of 0.1–1.0 mL/min, yielding a coating mass of 100–500 µg/cm² and a thickness of 2–10 µm. Drying is performed at 40°C under vacuum until residual chloroform is below 60 ppm and residual acetone below 5,000 ppm under ICH Q3C; these solvent thresholds are verified by USP <467>. Terminal sterilization by gamma irradiation at 25 kGy can reduce PLGA molecular weight and modify elution kinetics, so ethylene oxide processing or aseptic manufacturing is evaluated unless molecular weight reduction is shown to be batch-consistent. Compliance for the finished device includes ISO 10993-1:2018, ISO 14630:2012, ISO 13485:2016 clause 7.5.2 for production cleanliness, 21 CFR Part 820, and USP <71> for sterile device release. The terminal product is a drug-eluting coronary or peripheral stent with a biodegradable PLGA 75:25 coating that controls drug release during the first weeks to months after implantation.

    Scaling Sterile Filtration for Intra-Articular Depot Solutions

    An intra-articular depot formulation can be produced either as a lyophilized microsphere suspension or as an organic-solvent-free melt-extruded pellet. When a solution depot is selected, RESOMER RG 750 S is dissolved at 20–40% w/w in N-methyl-2-pyrrolidone or dimethyl sulfoxide, and the corticosteroid or small-molecule API is incorporated at a drug-to-polymer ratio of 1:10 to 1:30. Sterile filtration through a 0.2 µm polyvinylidene fluoride membrane is feasible only when the solution viscosity remains below approximately 500 mPa·s; higher-viscosity formulations require aseptic preparation and nanofiltration of the solvent before mixing because terminal heat or irradiation can degrade both the API and the PLGA backbone. For microsphere-based intra-articular products, the particle size is maintained with a Dv50 above 10 µm to reduce rapid phagocytosis by synovial macrophages after injection. Compliance includes USP <71>, USP <85>, USP <788>, USP <790>, ISO 10993-1:2018, and 21 CFR Part 211. The terminal product is a single-use prefilled syringe for ultrasound-guided intra-articular injection or a lyophilized microsphere vial reconstituted with diluent immediately before intra-articular administration.

    Free Quote

    Competitive RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618005193850

    Email: sales8@ascent-chem.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    RESOMER RG 750 S Bioresorbable PLGA Drug Delivery Grade is a biodegradable poly(D,L-lactide-co-glycolide) copolymer with a nominal lactide/glycolide molar ratio of 75:25 and an inherent viscosity specification of 0.16–0.24 dL/g when measured as a 0.1% solution in chloroform at 25 °C in accordance with ISO 1628-1:2021. The material is supplied as a white to off-white granulate or powder intended for parenteral drug delivery systems, including solvent-evaporation microspheres, subcutaneous implants, and in-situ gel-forming depots. RG 750 S carries a carboxylic acid terminal group; this end-group chemistry accelerates water uptake and hydrolytic ester cleavage relative to ester-capped 75:25 PLGA grades of comparable molecular weight. The acid terminus can also influence loading of amine-containing active pharmaceutical ingredients through ion-pair formation during solvent exchange. Residual methylene chloride, when dichloromethane is used in downstream processing, must be controlled below the ICH Q3C class 2 limit of 600 ppm in the finished dosage form.

    Specification Limits and Certified Test Methodology

    The following table summarises the typical specification envelope for RG 750 S. These values should be read with the manufacturer’s certificate of analysis because release limits may vary by supply agreement.

    ParameterAnalytical method / conditionTypical specification
    Lactide:glycolide molar ratio^1H NMR in deuterated chloroform74:26 to 76:24
    Inherent viscosity0.1% CHCl₃ at 25 °C, ISO 1628-1:20210.16–0.24 dL/g
    Glass transition temperatureDSC, 10 K/min, second heating40–50 °C
    Moisture contentPh. Eur. 2.5.12 Karl Fischer coulometry≤ 0.5%
    Residual methylene chlorideGC-headspace≤ 600 ppm per ICH Q3C
    Acid numberPotentiometric titrationReport result on certificate of analysis

    Molecular weight by size-exclusion chromatography with refractive-index detection and polystyrene calibration generally places RG 750 S in the weight-average molecular weight range of 10,000–20,000 Da; however, this is a relative result and not an absolute molecular mass. The glass transition temperature is low enough to permit melt processing below 120 °C, but high enough to avoid room-temperature flow of solidified implants.

    On a 10 L jacketed reactor equipped with a 4-blade pitched-turbine impeller, solvent-evaporation microsphere production using RG 750 S commonly employs an organic phase of dichloromethane at polymer concentrations between 5% and 20% w/v. The aqueous continuous phase contains poly(vinyl alcohol) at 1–2% w/v and is maintained at 15–25 °C. The emulsification step is sensitive to the low inherent viscosity of RG 750 S: when polymer concentration in the organic phase falls below 5%, the dispersed-phase viscosity may drop below 5 mPa·s, increasing the probability of satellite droplet formation and broad particle size distributions. Impeller tip speed is therefore kept in the range of 3.1–6.2 m/s; higher speeds produce submicron fragments carrying insufficient polymer mass to sustain release. After solvent evaporation, the hardened microspheres are washed with water for injection and lyophilised. Residual moisture is typically controlled below 0.5% by Karl Fischer titration because higher water content reduces glass-transition temperature and induces handling problems during terminal filling.

    For hot-melt extrusion, RG 750 S can be processed on a 16 mm co-rotating twin-screw extruder with an L/D ratio of 40:1. Barrel temperatures between 60 °C and 90 °C are usually sufficient to maintain screw torque below 70% of drive capacity at screw speeds of 100–200 min⁻¹. The melt temperature must not exceed 120 °C for prolonged residence times because intramolecular transesterification can generate lactide and glycolide monomers that act as plasticisers and broaden molecular weight distribution. When the torque signal oscillates by more than ±15%, feed bridging or local melt viscosity drop should be investigated. Nitrogen blanketing of the feed hopper is recommended when ambient relative humidity exceeds 60% RH, as moisture uptake during extrusion accelerates hydrolytic chain scission and reduces implant mechanical integrity.

    Why Does Carboxylic Acid Termination Accelerate Hydrolysis in 75:25 PLGA?

    In aqueous media, the free carboxylic acid terminus in RG 750 S lowers the local pH within the polymer matrix and catalyses ester-bond hydrolysis. Bulk erosion proceeds more rapidly than in an ester-capped 75:25 PLGA of equivalent inherent viscosity because the ester-capped grade lacks the additional acid source and hydrates more slowly. At pH 7.4 and 37 °C in phosphate-buffered saline, the acid-terminal effect is most pronounced in the early phase of degradation before autocatalytic internal acid accumulation equalises the pH gradient. This shifts the in vitro release curve of drugs with pH-dependent solubility; basic drugs that are protonated and entrapped as salts within the acidic PLGA matrix may show lower initial burst release than neutral drugs.

    The 75:25 lactide/glycolide ratio contributes to a longer degradation interval than 50:50 PLGA grades. The additional methyl side chains on lactide units impede water penetration and reduce hydrolysis rate constants, so RG 750 S is applied where month-scale release is required rather than the faster erosion window typical of 50:50 grades. The following comparative table positions RG 750 S against common related grades. Relative erosion rates are based on the same particle size, molecular weight band, and buffer environment; direct comparison across different particle sizes is not appropriate.

    Product / gradeLactide:glycolide ratioInherent viscosityEnd-groupRelative degradation rate
    RESOMER RG 750 S75:250.16–0.24 dL/gCarboxylic acidIntermediate
    RESOMER RG 502 H50:500.16–0.24 dL/gCarboxylic acidFaster than RG 750 S
    RESOMER RG 752 S75:250.16–0.24 dL/gEsterSlower than RG 750 S

    When the intended route is an in-situ forming depot, RG 750 S is dissolved in N-methyl-2-pyrrolidone or dimethyl sulfoxide at 20–40% w/w and injected into an aqueous physiological environment. The solvent exchange precipitates the polymer, forming an implant with a highly porous structure. The low inherent viscosity of RG 750 S reduces the force required for injection through a 21 G needle compared with higher-molecular-weight 75:25 PLGA grades. However, the reduced chain length also produces a less viscous depot after precipitation, and the initial burst release is frequently higher than that observed with a 0.45–0.60 dL/g grade. Formulators compensate by increasing polymer concentration, adding a hydrophobic plasticiser, or using a rate-limiting membrane coating.

    Microsphere encapsulation of water-soluble peptides and small molecules with RG 750 S commonly uses water-in-oil-in-water double emulsion. The primary emulsion is generated with a rotor-stator homogeniser at 8,000–20,000 min⁻¹; the secondary emulsification uses lower shear. Because RG 750 S solidifies quickly during solvent extraction, encapsulation efficiency for highly water-soluble compounds is more strongly influenced by primary emulsion viscosity than by continuous-phase pH. Poly(vinyl alcohol) concentration above 2% w/v reduces droplet coalescence but increases residual surfactant on the particle surface and may require additional washing steps.

    If Primary Amine-Containing Excipients Are Blended with RG 750 S

    Primary amines and strongly nucleophilic additives are incompatible with RG 750 S in melt and solution processing because they cleave the polyester backbone through aminolysis. This reaction is undesirable during hot-melt extrusion and can be identified by a rapid increase in melt flow rate or a drop in screw torque. In solution, the same aminolysis pathway reduces molecular weight during long hold times and can alter in vitro release kinetics before encapsulation is complete. Nucleophilic buffers such as tris(hydroxymethyl)aminomethane should not be used as the primary aqueous phase during solvent evaporation with this polymer; phosphate or acetate buffers at pH 7.0–7.4 are preferred. Storage under nitrogen at −20 °C is recommended for long-term stability. Once the container is opened, the polymer should be re-sealed with desiccant and held at 2–8 °C if consumed within 30 days. If exposure to 60% RH occurs for more than 24 h, vacuum drying at 40 °C for 12–24 h is required before hot-melt extrusion; lyophilised formulations should be kept below 0.5% moisture by Karl Fischer measurement.

    Residual solvent control is both a regulatory and a processing limitation. When dichloromethane is used for microsphere manufacture, the residual level must comply with the ICH Q3C class 2 limit of 600 ppm in the final drug product, and typical in-process controls aim below 300 ppm before release. Ethyl acetate, if substituted, falls under class 3 and carries a higher permitted concentration of 5,000 ppm, but its lower volatility and higher aqueous solubility require extended vacuum stripping. For sensitive peptide-loaded particles, terminal gamma irradiation above 25 kGy is not routinely recommended because chain scission increases the proportion of low-molecular-weight polymer and accelerates release; published data for this specific configuration is limited and requires product-specific validation.

    In dissolution testing with USP Apparatus 4 flow-through cells at 37 °C and pH 7.4, RG 750 S microspheres typically exhibit a biphasic release profile: an initial burst during the first 24 h, a diffusion-controlled lag phase, and a later erosion-accelerated phase. The burst phase is sensitive to particle size and surface porosity; spray-dried particles with specific surface area above 10 m²/g by nitrogen adsorption may release 20–30% of the payload within 6 h, whereas dense solvent-evaporation microspheres with residual solvent below 300 ppm can maintain the burst below 10%. The release-rate inflection point coincides with mass loss of roughly 5–10% and an internal pH drop below 3.0. This behavior distinguishes RG 750 S from higher-lactide or higher-molecular-weight PLGA products that exhibit longer lag periods and lower initial release under identical process conditions.

    Top